Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Taxol, a unique tubulin active agent, was found to demonstrate a marked schedule-dependent synergistic interaction with cisplatin (DDP) in the killing of human ovarian carcinoma 2008 cells in vitro as determined by median effect analysis. The interaction was highly synergistic when 19 h taxol exposure was followed by 1 h concurrent exposure to taxol and DDP. The combination indices (CIs) on this schedule were 0.11 +/- 0.1, 0.25 +/- 0.15 and 0.39 +/- 0.14 at 20%, 50% and 80% cell kill respectively. However, the interaction was antagonistic when 1 h exposure to DDP was followed by 20 h exposure to taxol, or when cells were exposed to DDP and taxol for 1 h concurrently. When taxol preceded DDP, synergy was also observed with the 11-fold DDP-resistant 2008/C13*5.25 subline, which yielded CI values of 0.21 +/- 0.02, 0.30 +/- 0.11 and 0.31 +/- 0.17 at 20%, 50% and 80% cell kill respectively. At an IC50 concentration, taxol had no effect on [3H]cis-dichloro(ethylenediamine) platinum uptake, on the permeability of the plasma membrane or on glutathione or metallothionein levels in 2008 or 2008/C13*5.25 cells. Mitotic arrest in these cells was observed only at taxol concentrations well above those required for synergy with DDP, suggesting that the mechanism underlying the synergistic interaction was not a taxol-induced alteration in cell cycle kinetics. Of additional interest was the fact that the 2008/C13*5.25 cells were hypersensitive to taxol, and that this was partially explained by an alteration in the biochemical pharmacology of taxol. Although cellular taxol accumulation reached steady state within 2 h in both cell lines, taxol efflux was slower and the taxol was more extensively bound in 2008/C13*5.25 cells than in 2008 cells. In addition, the 2008/C13*5.25 cells had only 55% of the parental levels of beta-tubulin content. However, in another pair of DDP-sensitive and -resistant ovarian cell lines no taxol hypersensitivity and no change in beta-tubulin content was observed, indicating that the DDP-resistant and taxol-hypersensitive phenotypes do not segregate together. We conclude that taxol interacts synergistically with DDP in a manner that is highly schedule dependent, and that the hypersensitivity of 2008/C13*5.25 cells no taxol is unrelated to the mechanism of synergy. These in vitro observations suggest that drug schedule will be an important determinant of the activity and toxicity of the DDP and taxol drug combination in clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Cited by
Spencer, C. M., & Faulds, D. (1994) · Drugs · doi:10.2165/00003495-199448050-00009 · Cited by 396
Taxanes: A New Class of Antitumor Agents
Huizing, M. T., Misser, V. H. S., Pieters, R. C., ten Bokkel Huinink, W. W., Veenhof, C. H. N., Vermorken, J. B., Pinedo, H. M., & Beijnen, J. H. (1995) · Cancer Investigation · doi:10.3109/07357909509031919 · Cited by 285
Hurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., Velez, P., Pauletti, G., Powell, J. E., Pegram, M. D., & Slamon, D. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8886 · Cited by 245
Cai, L., Xu, G., Shi, C., Guo, D., Wang, X., & Luo, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.044 · Cited by 151
“It has been reported that the synergistic combinations of CDDP and PTX depends largely on the dosing sequence, time interval and dose concentrations of these two drugs [32].”
BackgroundSong, W., Tang, Z., Li, M., Lv, S., Sun, H., Deng, M., Liu, H., & Chen, X. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.11.026 · Cited by 126
“The PTX + CDDP combination of free drugs has shown a good synergism effect against a wide range of cancer cell lines due to the different mechanisms by which PTX and CDDP act [8,9].”
BackgroundBiodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer
Desale, S. S., Cohen, S. M., Zhao, Y., Kabanov, A. V., & Bronich, T. K. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.026 · Cited by 110
Prediction of resistance to chemotherapy in ovarian cancer: a systematic review
Lloyd, K. L., Cree, I. A., & Savage, R. S. (2015) · BMC Cancer · doi:10.1186/s12885-015-1101-8 · Cited by 87
Rosati, G., Riccardi, F., Tucci, A., De Rosa, P., & Pacilio, G. (2000) · Tumori Journal · doi:10.1177/030089160008600306 · Cited by 17
Li, J., Li, Z., Li, M., Zhang, H., & Xie, Z. (2015) · Journal of Applied Polymer Science · doi:10.1002/app.41440 · Cited by 16
Metadata
- Authors
- Jekunen, A., Christen, R., Shalinsky, D., & Howell, S.
- Venue
- British Journal of Cancer
- Published
- 1994-02
- Volume
- 69
- Issue
- 2
- Pages
- 299-306
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2049306821
- Cited by
- 128
- References
- 2
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.